Download MendeleyDiscovery of AZD8154, a Dual PI3K gamma delta Inhibitor for the Treatment of Asthma.
Perry, M.W.D., Bjorhall, K., Bold, P., Brulls, M., Borjesson, U., Carlsson, J., Chang, H.A., Chen, Y., Eriksson, A., Fihn, B.M., Fransson, R., Fredlund, L., Ge, H., Huang, H., Karabelas, K., Lamm Bergstrom, E., Lever, S., Lindmark, H., Mogemark, M., Nikitidis, A., Palmgren, A.P., Pemberton, N., Petersen, J., Rodrigo Blomqvist, M., Smith, R.W., Thomas, M.J., Ullah, V., Tyrchan, C., Wennberg, T., Westin Eriksson, A., Yang, W., Zhao, S., Oster, L.(2021) J Med Chem 64: 8053-8075
- PubMed: 34080862
- DOI: https://doi.org/10.1021/acs.jmedchem.1c00434
- Primary Citation of Related Structures:
7OI4, 7OIJ, 7OIL, 7OIS - PubMed Abstract:
Starting from our previously described PI3Kγ inhibitors, we describe the exploration of structure-activity relationships that led to the discovery of highly potent dual PI3Kγδ inhibitors. We explored changes in two positions of the molecules, including macrocyclization, but ultimately identified a simpler series with the desired potency profile that had suitable physicochemical properties for inhalation. We were able to demonstrate efficacy in a rat ovalbumin challenge model of allergic asthma and in cells derived from asthmatic patients. The optimized compound, AZD8154, has a long duration of action in the lung and low systemic exposure coupled with high selectivity against off-targets.
Organizational Affiliation:
Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-431 83, Sweden.
